A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship Between Patient Outcomes, Treatment Regimens and Molecular Profiles
Latest Information Update: 27 Sep 2024
Price :
$35 *
At a glance
- Drugs Bortezomib (Primary) ; Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Pomalidomide (Primary) ; Thalidomide (Primary)
- Indications Multiple myeloma
- Focus Pharmacodynamics; Pharmacogenomic
- Acronyms CoMMpass; MMRF CoMMpass study
- 25 Sep 2024 According to a Multiple Myeloma Research Foundation Media Release, new data in oral and poster presentation to be shared at the 21st International Myeloma Society (IMS) Annual Meeting, being held in Rio De Janeiro, Brazil, September 25-28, 2024.
- 19 Aug 2024 According to a Multiple Myeloma Research Foundation Media Release, data from this study were published in Nature Genetics.
- 19 Aug 2024 Results were published in a Multiple Myeloma Research Foundation Media Release.